REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

OA Location

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.TPS9145

Author(s)

Seckl, Michael

Ghorani, Ehsan

Quartagno, Matteo

Blackhall, Fiona Helen

Gilbert, Duncan C

more

Type

Journal Article

Date Issued

2023-06-01

Date Acceptance

2023-06-01

Citation

Journal of Clinical Oncology, 2023, 41 (16 Suppl.), pp.TPS9145-TPS9145

URI

http://hdl.handle.net/10044/1/107153

DOI

https://www.dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9145

ISSN

0732-183X

Publisher

American Society of Clinical Oncology

Start Page

TPS9145

End Page

TPS9145

Journal / Book Title

Journal of Clinical Oncology

Volume

41

Issue

16 Suppl.

Copyright Statement

© 2023 by American Society of Clinical Oncology

Identifier

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001053772005494&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb

Subjects

Life Sciences & Biomedicine

Oncology

Science & Technology

Publication Status

Published

Date Publish Online

2023-05-31